Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05464992

Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI

Standard Magnetic Resonance Imaging (MRI) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. However, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions.

Chemical exchange saturation transfer (CEST) allow to overcome some limitations of proton magnetic resonance spectroscopy (1H-MRS) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. Moreover, CEST technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glioma Brain Diseases Brain Metastases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nervous System Diseases Nervous System Neoplasms Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

France Institut de cancérologie Strasbourg Europe

Strasbourg, France

Location status: Recruiting

Location contact

Caroline BUND, MD, PhD

SUB_INVESTIGATOR

Izzie-Jacques NAMER, MD, PhD

PRINCIPAL_INVESTIGATOR

Manon VOEGELIN

CONTACT

[email protected]

About this study

For this study the investigators propose to include an additional CEST sequence in standard PET/MRI exam in order to obtain a cartography with biochemical informations from tissues in patients with glioma or brain metastases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to:

  • Preoperative evaluation of a cerebral expansion lesion
  • Evaluation of glioma recurrences
  • Evaluation of brain metastases
  • Evaluation of recurrence of metastases

Exclusion criteria

  • Contraindication to the realization of an MRI
  • Minor or patients placed under guardianship or supervision
  • Patients deprived of liberty
  • Patients placed under judicial protection
  • Patients that are not able to express their consent
  • Pregnant and breastfeeding women

Treatment and study plan

Additional CEST sequences during PET/MRI exam

Other

CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare

Primary outcomes

  1. Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases

    Time frame: through study completion, up to 14 years

    Evaluation at the cerebral level on the acquisition images of residual volume in MRI

  2. Obtention, from a set of brain PET-MRI images, of an intratissular pH mapping in patients with glioma or brain metastases

    Time frame: through study completion, up to 14 years

    Evaluation at the cerebral level on the acquisition images of tumoral metabolic activity in PET

Secondary outcomes

  1. Correlate intratissular pH mapping and location of recurrence

    Time frame: through study follow-up, up to 10 years

  2. Correlate average pH of the tumor and histopathology

    Time frame: through study follow-up, up to 10 years

  3. Correlate average pH of the tumor and Disease-Free Survival (DFS)

    Time frame: through study follow-up, up to 10 years

  4. Correlate average pH of the tumor and Overall survival (OS)

    Time frame: through study follow-up, up to 10 years

Study contacts

Contact information is provided by the study sponsor or research team.

Claire VIT

CONTACT

[email protected]

(0)368339523 ext. 33

Manon VOEGELIN

CONTACT

[email protected]

(0)368339523 ext. 33

Sponsors and collaborators

Lead sponsor

Centre Paul Strauss

Other

Registry information

Acronym: GlioCEST

Important dates

Study start
2022
Primary completion
2036
Study completion
2036
First posted
Jul 19, 2022
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.